Protein kinase CK2 is an ubiquitous and constitutively active kinase, which phosphorylates many cellular proteins and is implicated in the regulation of cell survival, proliferation and transformation. We investigated its possible involvement in the multidrug resistance phenotype (MDR) by analysing its level in two variants of CEM cells, namely S-CEM and R-CEM, normally sensitive or resistant to chemical apoptosis, respectively. We found that, while the CK2 regulatory subunit b was equally expressed in the two cell variants, CK2a catalytic subunit was higher in R-CEM and this was accompanied by a higher phosphorylation of endogenous protein substrates. Pharmacological downregulation of CK2 activity by a panel of specific inhibitors, or knockdown of CK2a expression by RNA interference, were able to induce cell death in R-CEM. CK2 inhibitors could promote an increased uptake of chemotherapeutic drugs inside the cells and sensitize them to drug-induced apoptosis in a co-operative manner. CK2 blockade was also effective in inducing cell death of a different MDR line (U2OS). We therefore conclude that inhibition of CK2 can be considered as a promising tool to revert the MDR phenotype.
Introduction
CK2 is an ubiquitous, highly conserved and pleiotropic Ser/Thr kinase, endowed with constitutive activity, independent of any known second messenger or phosphorylation events (Pinna, 2002) . CK2 has a heterotetrameric structure, composed of two catalytic (a and/or a 0 ) and two regulatory (b) subunits. In vitro, the recombinant catalytic subunits are active either alone or combined with the b subunits, whose presence however alters the protein substrate specificity and confers susceptibility to polybasic effectors, notably polyamines and histones (Pinna, 1990) . However, at present no evidence of a dynamic regulation operated by the b-subunit in vivo has been provided, where CK2 is usually found in its holoenzymatic a 2 b 2 form, whose spontaneous dissociation under physiological conditions remains a matter of conjecture (Filhol et al., 2004) . CK2 phosphorylates a huge number of protein substrates, involved in many fundamental cell processes (Meggio and Pinna, 2003) , and is essential for cell life. It is frequently upregulated in human cancers (Guerra and Issinger, 1999) , and transgenic expression of CK2a in lymphocytes is oncogenic (Seldin and Leder, 1995) and accelerates leukemia development induced by other oncogenes (Kelliher et al., 1996) . Recently, a global anti-apoptotic role of CK2 has been disclosed (reviewed by Ahmed et al., 2002; Litchfield, 2003) , whose mechanism is seemingly multifactorial and only partly understood.
Considering such an intimate implication of CK2 in cell survival, we wondered if it could be possibly involved in the multidrug resistance phenotype (MDR) as well. MDR denotes the resistance to drug-induced apoptosis frequently developed by cancer cells; it is a phenomenon of paramount medical relevance, being mainly responsible for the failure of cancer therapy. Although apoptosis resistance is the result of cell selection upon treatment with a particular drug, the same cells frequently develop a cross-resistance toward other compounds, even not structurally related. The mechanisms underlying MDR are undoubtedly multiple, and many hypotheses have been proposed, including alteration in genetic features, DNA repair, drug target molecules, metabolic and growth pathways (Sawicka et al., 2004) . A prominent role is attributed to the membrane transport system consisting of the so called MDR proteins (Borst, 1997) . These are ATPdependent and highly promiscuous transporters, which extrude cytotoxic molecules from the cell; among others, this group of proteins includes the P-glycoprotein (P-gp), encoded by the MDR1 gene, which is the drug pump most frequently found in MDR cells (Ling, 1997) .
The involvement of CK2 in the MDR phenomenon has never been specifically investigated. However, besides the general anti-apoptotic role of this kinase, additional observations suggest its possible relevance in this context. First, the P-gp is a known substrate of CK2 (Glavy et al., 1997) , whose phosphorylation sites have also been mapped, though the effect of CK2-dependent phosphorylation on the P-gp functionality has never been elucidated. Secondly, overexpression of CK2 in a MDR glioma cell line has been reported and considered responsible for the high in vivo phosphorylation of its substrate DNA topoisomerase II (Matsumoto et al., 2001) . Given these premises, we decided to perform a comparative analysis of CK2 in two variants of human T lymphoblastoid CEM cell line, one normally sensitive to drug-induced apoptosis, referred to as S-CEM, while the other, referred to as R-CEM, derived from the parental one by selection with vinblastin treatment, and displaying a cross-resistance to many other chemotherapeutic drugs (Dupuis et al., 2003, and Figure 5) . In these two cell variants, we thoroughly examined the expression of CK2 subunits and its endogenous catalytic activity, and we analysed the possibility of using CK2-specific inhibitors to overcome the MDR phenotype.
Results
Expression of CK2 catalytic and regulatory subunits in R-CEM and S-CEM We first examined the expression of CK2 by performing western blot analysis of total lysates of S-CEM and R-CEM, with antibodies toward the CK2 catalytic (a/a 0 ) and regulatory (b) subunits. As shown in Figure 1a , while CK2b was expressed at similar levels, we found a significantly higher amount of CK2a in R-CEM than in S-CEM; the same result was obtained by using either a C-or a N-terminal a-antibody (ruling out the hypothesis of a different proteolytic cleavage in the two types of cells), and with other polyclonal and monoclonal antibodies (see Materials and methods). On the contrary, a 0 was almost undetectable both in S-CEM and R-CEM (not shown). The comparison was performed also after immunoprecipitation of CK2a, instead of loading total lysates, and the results were similar: despite equivalent amount of b, a higher amount of a was reproducibly present in the immunoprecipitate from R-CEM (Figure 1b) .
When we analysed the CK2a mRNA expression by means of semiquantitative PCR, we found comparable amounts in S-CEM and R-CEM (Figure 1c ), suggesting that the different level of a in the two variants was due to altered regulation at the protein level rather than at transcriptional level. To highlight a possible different turnover of CK2a protein, we treated cells with cycloheximide, to block protein synthesis, and we followed the decrease of a by western blot: the results, shown in Figure 2 , disclose a markedly slower protein disappearance in R-CEM as compared to S-CEM.
We next analysed the distribution of CK2a in different subcellular compartments: it turned out that its overall higher level is predominantly accounted for by the cytosolic and nuclear fractions, whereas in mitochondria and microsomes S-CEM and R-CEM display similar level of CK2a (Figure 3a) . A relative quantification of CK2 a-and b-subunits in the cytosol and nuclei of the two cell variants was performed by comparative analysis with recombinant CK2 holoenzyme (a 2 b 2 ), containing equimolar amounts of the two subunits. The ratio of a/b in S-CEM was very similar to that calculated for the recombinant holoenzyme, while in R-CEM a exceeded b by about four to fivefold both in the cytosol and in the nucleus (Figure 3b ).
CK2 activity in R-CEM and S-CEM
To assess if higher level of CK2 catalytic subunit in R-CEM cells also reflects in increased phosphorylation of endogenous substrates, R-CEM and S-CEM were incubated with 32 P i either in the absence or presence of specific CK2 inhibitors, and 32 P-incorporation into cellular proteins was evaluated by SDS/PAGE followed by blotting and autoradiography. As shown in Figure 4 , we found that protein phosphorylation is more pronounced in R-CEM than in S-CEM cells; to be sure that the observed differences were not due to a higher rate of 32 P i loading in R-CEM, we performed the experiment at different times (partially shown in Figure 4a) , finding that at 4 h the cellular ATP pool is already at isotopic equilibrium and that the ratio between R-CEM and S-CEM global phosphorylation is constant. Figure 4a provides the clear cut demonstration that CK2 activity substantially contributes to protein phosphorylation in R-CEM, as judged from the adverse effect of the CK2 inhibitor TBB on the radiolabeling of several bands. Note in particular, the presence of several TBB-sensitive bands in the R-CEM lanes, which are almost undetectable in the S-CEM lanes. Similar results were obtained treating cells with other CK2 inhibitors, either structurally related or not to TBB (not shown). Figure 4 also shows that the phosphorylation degree of two CK2 target sites (Ser129 of Akt, Di Maira et al., 2005 and Thr 117 of BAD, Klumpp et al., 2004) , detected by phospho-specific antibodies, is higher in R-CEM than in S-CEM. From all these data, it can be concluded that CK2-catalysed protein phosphorylation is much more pronounced in R-CEM cells, consistent with their higher content in CK2a.
Surprisingly, such a higher CK2 activity disclosed in intact R-CEM as compared to S-CEM cells could not be detected in cell lysates, where CK2 activity, monitored with a specific peptide substrate, was comparable in S-CEM and R-CEM (not shown). The results were similar whether the activity was measured in crude cell lysates, subcellular fractions, or after immunoprecipitation of CK2a, either towards peptide or protein substrates, such as casein or calmodulin. This is probably the consequence of in vitro artifact(s) arising from cell lysis and association of CK2 with inhibitory molecules. In fact, no linear increase could be observed of CK2 activity from the R-CEM by increasing the aliquot of lysate tested (not shown).
Treatment of CEM cells with CK2-specific inhibitors and siRNA Since many CK2-specific inhibitors have been shown to induce apoptosis in several cell types (reviewed by Sarno et al., 2005a) , we tested their effect on CEM cell viability. As expected, R-CEM cells were refractory to treatment with a number of chemotherapeutic drugs, which eradicate S-CEM cells. In contrast, responsiveness to a panel of CK2 inhibitors was similar with either S-CEM or R-CEM cells ( Figure 5a ): when used at a fixed concentration (20 mM), the effect of CK2 inhibitors was roughly proportional to their IC 50 values for CK2 (with the remarkable exception of MNA, see below). Although these inhibitors are highly selective for CK2, we performed RNA interference experiments to exclude completely the possibility of an aspecific effect. In this set of experiments, we knocked down the expression of CK2a and then evaluated the apoptosis by detecting the caspase-dependent PARP degradation and the apoptotic nucleosome formation. The results, shown in Figure 5b , demonstrated that both S-CEM and R-CEM cells undergo apoptosis whenever CK2a amount is reduced. Of particular interest for this work is the case of R-CEM, where, despite an only partial CK2a reduction, a higher degree of apoptosis was observed in cells treated with the CK2a-specific siRNA, compared to aspecific siRNA.
As shown in Figure 5a , the CK2 inhibitor MNA was almost ineffective in R-CEM, despite its remarkable efficacy in S-CEM; interestingly, this inhibitor, although endowed with a fairly good inhibitory efficiency towards CK2 holoenzyme (IC 50 ¼ 0.30 mM), is much less effective towards its isolated catalytic subunit (IC 50 ¼ 2.5 mM) (Salvi et al., 2006) . Figure 5c shows a direct comparison of the dose-dependent effect on R-CEM viability of MNA and its related analog, MNX, whose IC 50 values are instead similar with either CK2 holoenzyme or CK2a. These data support the view that R-CEM cell survival is ensured by the 'free' catalytic subunit of CK2 (CK2a, not assembled with b). Consistently, cells from a (Figure 6a) . Interestingly, the comparison between the S-U2OS (wild-type line) and R-U2OS (MDR variant) revealed a higher sensitivity to the inhibition of CK2 of the resistant cells, which also die in response to siRNA knocking down of CK2 expression (Figure 6b ).
FACS analysis indicated that the CK2 inhibitors induced R-CEM cell death by an apoptotic mechanism: for example, after a 16 h treatment with the inhibitor TBI, the apoptotic cell fraction, representing about 2.971.2% of not-treated R-CEM, increased to about 3373.5% (not shown).
The proapoptotic efficacy of CK2 inhibitors in R-CEM rules out that they are readily extruded from the cell by P-gp, also consistent with the capability of TBB to alter the in vivo phosphorylation pattern. This could simply mean that CK2 inhibitors are not good substrates for the R-CEM machinery responsible for the extrusion of chemotherapeutic drugs. It was also possible, however, that CK2 inhibition impairs the functionality of MDR protein(s), thus ultimately overcoming the MDR phenotype of R-CEM cells. To assess this possibility, we exploited the fluorescence of doxorubicin, and evaluated its accumulation after 30 min cell preincubation in the presence or in the absence of CK2 inhibitors. As expected, not pretreated R-CEM cells accumulated much lower amounts of doxorubicin as Figure 3 Subcellular distribution of CK2 subunits in S-CEM and R-CEM. (a) Ten microgram of proteins from the indicated fraction were analysed by western blot with anti-CK2a C-terminal antibodies. The quality of cytosolic and nuclear fractions was checked by western blot for specific marker proteins, namely lactate dehydrogenase (LDH) and lamin B, respectively, as indicated. (b) Twenty microgram of cytosolic and nuclear proteins from S-CEM and R-CEM were analysed by western blot with anti-CK2a N-terminal or anti-CK2b antibodies, along with the indicated amounts of recombinant CK2 a 2 b 2 (upper panel). The CK2 subunit amounts present in cell fractions (lower panel) were calculated by densitometric analysis and extrapolation from the calibration curve built on the recombinant CK2 signal; the experiment was performed twice, with two different cell lysate preparations; the reported bars are the mean values7s.e.m. compared to S-CEM; CK2 inhibitors induced a modest increase in the uptake of drug in S-CEM, while in R-CEM such an increase was significantly higher (Figure 7a ). Figure 7b shows that the dose-dependent effect of TBB on doxorubicin uptake by R-CEM was paralleled by CK2 inhibition, consistent with the notion that CK2 inhibition is responsible for the favorable effect of TBB on doxorubicin accumulation. Given these premises, we hypothesized that CK2 inhibitors could reduce the threshold of R-CEM sensitivity to chemotherapeutic drugs, such as vinblastine. To validate this hypothesis, we treated cells with increasing concentrations of vinblastine, in the absence or in the presence of a constant concentration of the CK2 inhibitor. At sub-lethal concentrations the inhibitors had no effect even in the presence of the drugs, the efficacy at higher concentrations however, was dramatically increased by the simultaneous administration of vinblastine (not shown). The cell death induced by the combined treatment was due, at least in part, to apoptosis, as judged by the increased cleavage of the caspase substrate PARP protein (Figure 8a ). Similar Figure 4 CK2 activity in S-CEM and R-CEM. (a) Cells were loaded with 32 P i for the indicated times; where indicated, 20 mM TBB was added during 32 P i loading. 20 mg of total proteins were analysed by SDS/PAGE and blotting, followed by autoradiography (radioactivity) and western blot with anti-actin, as a loading control. Lanes 1-4 and 5-6 correspond to two separate experiments. For lanes 5 and 6, a quantitative analysis of radioactivity incorporated into the bands was performed by means of the OptiQuant Image Analysis software (Canberra-Packard, Schwadorf, Austria); bands whose intensity decrease by 50% or more in TBB-treated cells are pinpointed. (b) Upper part: equal amounts of Akt were immuno-precipitated from S-CEM and R-CEM lysates, and analysed by western blot with the CK2 target site Ser129 phospho-specific antibodies (Di Maira et al., 2005) and Akt total antibody, as indicated. Lower part: Ten microgram of total lysate from S-CEM and R-CEM were analysed by western blot with the CK2 target site BAD Thr117 phospho-specific antibodies (Klumpp et al., 2004) or BAD total antibody, as indicated. Where present ( þ TBB), 20 mM TBB was administrated to the cells for 3 h before lysis. On the right part of both panels, quantification of phospho-Ser129 Akt and phosphoThr117 BAD is shown, obtained by normalization to the total amount of Akt and BAD, respectively.
Implication of CK2 in the MDR phenotype of CEM cells G Di Maira et al results were obtained with different combinations of CK2 inhibitors (for example, TBI, TBB,) and chemotherapeutic drugs (for example, etoposide). To check if the effect of the combined treatment was additive or synergistic, we calculated the combination index by simultaneously increasing the concentrations of both compounds (see Materials and methods); the results, shown in Figure 8b , confirmed a synergism between vinblastine and TBB.
To further prove that the existence of 'free' a is sufficient to ensure a higher degree of cell survival, we finally tried to overexpress CK2a in S-CEM, to evaluate its contribution to the resistant phenotype. Unfortunately, despite intensive efforts, CEM cells turned out to be fully refractory to the transfection, and all our attempts to induce ectopic overexpression of CK2a in these cells were unsuccessful. Nevertheless, we were able to show in different cell models, such as HEK 293T (not shown) or U2OS (Figure 9 ), that the overexpression of CK2a promoted a higher resistance to drug-induced apoptosis.
Discussion
In the present study, we investigated the level of protein kinase CK2 in two variants of CEM cells, and we found 
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G Di Maira et al a higher expression of CK2a catalytic subunit in the MDR variant (R-CEM), as compared to wild-type cells (S-CEM), accompanied by a higher cellular CK2 catalytic activity, as judged from the phosphorylation of endogenous proteins sensitive to CK2 inhibitors. The reason for the higher amount of CK2a appears to reside in a slower turnover in R-CEM, since the mRNA levels are very similar to S-CEM, while the half-life of CK2a protein is more than doubled. It will be interesting to check whether this is due to an increased translation (for example, as a consequence of mRNA deregulation) or to a blockage in protein degradation, or, eventually, to both mechanisms. Our data indicate that, among the many adaptations already described which may contribute to the MDR phenotype, CK2 overexpression should be also considered as an additional mechanism that can be selected to ensure cell survival. Indeed, higher levels of CK2 had been already reported in a glioma MDR cell line (Matsumoto et al., 2001) , and, considering the pro-survival function of CK2, it is conceivable that CK2 overexpression frequently occurs whenever apoptosis resistance is observed. However, we cannot consider it as an absolute requirement for the MDR phenotype, since, for example, we did not find any significantly different CK2 expression when we analysed a wild type and a MDR variant of an osteosarcoma cell line (U2OS) (unpublished data and Figure 6 ). Our present view, therefore, is that CK2 overexpression, whenever occurring, contributes to confer high level of resistance, which is achieved when more than one mechanism co-operate to the final phenotype. The relevant contribution of CK2 to the R-CEM resistance is highlighted by the usage of CK2 inhibitors, showing that MDR cells undergo apoptosis when CK2 activity is blocked, thus escaping the problem of drug extrusion by P-gp. The wide panel of different CK2 inhibitors used, their generally narrow specificity (Sarno et al., 2005a) and the good correlation between the induced effect and their efficacy in inhibiting CK2, along with the results Figure 6 Effect of CK2 inhibitors on U2OS cell viability, (a) S-U2OS and R-U2OS cells were treated for 40 h with the vehicle (0.5% (v/v) DMSO), or increasing concentrations of the indicated CK2 inhibitors. Viability was evaluated with the method of MTT. (b) S-U2OS and R-U2OS cells were transfected with 120 nM aspecific siRNA (Ctrl) or 120 nM CK2a-specific siRNA. After 76 h, 10 mg of proteins from total cell lysate were analysed in western blot with the indicated antibodies, while the apoptosis degree was evaluated by measuring nucleosome formation with the Cell Death Detection ELISA kit (Roche), and the results are shown by the bar graph. Nucleosome enrichment was calculated from the ratio between the signal in CK2a-siRNA treated cells and aspecific-siRNA-treated cells.
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obtained by knocking down CK2a expression with siRNA, make us confident that the observed cell death is actually due to CK2 blockade. It is worth noting that CK2 inhibitors, as well as CK2a-specific siRNA, are able to induce cell death also in the MDR variant of U2OS cells, and that their effect is even higher that in the wild type variant of the same line (Figure 6 ).
Although we do not have a clear explanation for the lower responsiveness of the S-U2OS cells to CK2 downregulation, it should be borne in mind that this line has been reported to be rather refractory to apoptosis (Cenni et al., 2004) . Alternatively, we can speculate that the MDR line variant, R-U2OS, although not expressing higher level of CK2, more strictly relies (a) R-CEM were treated for 24 h with vehicle (À), or 0.1 mg/ml vinblastine (Vbl), 40 mM IQA, 5 mM TBI, or combined compounds, as indicated. 10 mg of cell lysate were analysed by western blot with anti-PARP antibodies. The migration of the full-length PARP protein and its caspase-cleaved product are indicated by the arrows. (b) R-CEM viability was assessed by the MTT method after 40 h treatment with increasing concentrations of both vinblastine and TBB, administrated alone or in combination. Viability was plotted as function of Vbl concentrations (left panel), or TBB concentrations (right panel). Combination index (CI) was calculated as described by Giovannetti et al. (2004) , where a value o1 indicates synergism.
Implication of CK2 in the MDR phenotype of CEM cells G Di Maira et al on CK2 activity for their survival as compared to normal cells. In any case, our results suggest that CK2 inhibition could be considered as a general tool to counteract the MDR phenotype. Interestingly, CK2 inhibitors are also able to sensitize cells to chemotherapeutic drugs, an effect which seems to be mediated, at least in part, by the downregulation of P-gp activity itself. Although the phosphorylation of P-gp by CK2 has been known for several years (Glavy et al., 1997) , here we show for the first time that the drug accumulation in P-gp expressing cells is increased in a manner proportional to the degree of CK2 inhibition, thus providing a strong indication for a functional link between P-gp and CK2.
A remarkable outcome of our study on R-CEM cells was the observation that only the catalytic a-subunit of CK2 was overexpressed in R-CEM, while the level of the b regulatory subunit was very similar to that found in S-CEM. Also the amount of the catalytic isoform a 0 (hardly detectable, being its level much lower than a, in both cell variants) was similar. The data therefore are indicative of an unbalanced expression of CK2 catalytic and regulatory subunits, implying the existence in R-CEM of a not combined with b in the canonical tetrameric structure. The possibility that CK2 subunits are present in the cells as independent entities has often been proposed (Allende and Allende, 1998; Filhol et al., 2004) ; here we provide a clear cut example of its occurrence, also indicative of a role for CK2a in ensuring a higher degree of cell survival. This is further supported by the results of Figure 9 , where S-U2OS cells overexpressing a roughly double amount of CK2a survive significantly more than control cells to drug-induced apoptosis. In this respect, our data are consistent with already published works; very recently, Tapia et al. (2006) and Ahmad et al. (2007) , for example reported on the protective effect from cytotoxic drugs of CK2a ectopically expressed in HEK-293T and prostatic cancer cells, respectively. Interestingly, Guo et al. (2001) showed that the overexpression of a alone protects cells from chemical apoptosis similarly or even better than the expression of a and b together. On the other hand, it is generally acknowledged that the oncogenic potential of CK2 is related to the overexpression of the catalytic subunit, since it displayed its transforming effects in the absence of b (Seldin and Leder, 1995; Kelliher et al., 1996; Landesman-Bollag et al., 1998; Orlandini et al., 1998) .
A part from these considerations, a robust argument supporting the role of CK2a in R-CEM cell survival is provided by our experiments of Figure 5 , showing that a particular inhibitor, MNA, much more effective in vitro towards CK2 a 2 b 2 than towards CK2a (Salvi et al., 2006) , was poorly effective on R-CEM viability, as compared to other inhibitors displaying similar efficacy towards CK2a and holoenzyme. This shows that in these cells the excess of a, not combined with b, is sufficient to counteract cell death. At present, we do not know if this catalytic form of CK2 is actually present as a monomer, or rather combined in other molecular complexes; it will be also important to search for protein substrates eventually phosphorylated in R-CEM by CK2a, but not by a 2 b 2 . What we can say is that CK2, recently proposed as an oncogenic target (Ahmad et al., 2005; Seeber et al., 2005) , should be taken into special consideration whenever the tumor displays drug resistance, given the ability of CK2 inhibitors to revert the MDR phenotype.
Materials and methods

Materials
Antibodies. CK2a-subunit antisera were raised in rabbit against the sequence of the human protein at C terminus (376-391), N terminus (2-15), or central region (188-202), CK2a-subunit monoclonal antibodies were from Calbiochem (Darmstadt, Germany) (1AD9), CK2b-subunit antibodies were raised in rabbit against the whole human protein, and also purchased from BD Transduction Laboratories (Erembodegen, Belgium), CK2a 0 -subunit, total Akt, actin, lactate dehydrogenase, and lamin B antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA, USA), PARP antibodies were from Roche (Basel, Switzerland), Akt Sp129 phospho-specific antibodies were raised in rabbit as described elsewhere (Di Maira et al., 2005) , BAD antibodies were from Cell Signaling Technology (Danvers, MA, USA), BAD Tp117 phosphospecific antibodies were kindly provided by Dr Klumpp (Munster, Germany) .
Inhibitors. TBB was synthesized as in Szyszka et al. (1995) , IQA as in Sarno et al. (2005) , TBI and 2a as in Pagano et al. (2004); and MNA and MNX as in De Moliner et al. (2003) .
Vinblastine, doxorubicin, etoposide were from SigmaAldrich (Milano, Italy).
Recombinant CK2a and a 2 b 2 were kindly provided by Dr Sarno (Padova, Italy). Cell culturing and treatment Human T lymphoblastoid CEM cell line (normal sensitive, S-CEM and its MDR variant, R-CEM, selection with 0.1 mg/ml vinblastine) were maintained in RPMI 1640 (Sigma-Aldrich), supplemented with 10% fetal calf serum (FCS), 2 mM L-glutamine, 100 U/ml penicillin and 100 mg/ml streptomycin, in an atmosphere containing 5% CO 2 . To the R-CEM medium, 0.1 mg/ml vinblastine was routinely added. Human osteosarcoma U2OS cell line (normal sensitive, S-U2OS and its MDR variant, R-U2OS (Cenni et al., 2004) ) were cultured in D-MEM (Sigma-Aldrich) supplemented with 10% FCS, 2 mM L-glutamine, 100 U/ml penicillin and 100 mg/ml streptomycin, in an atmosphere containing 5% CO 2 . Cell treatments with CK2-specific inhibitors were performed in the culture medium, but with 1% FCS. At the end of the incubations, cells were centrifuged, washed and lysed as indicated below.
Cell viability and apoptosis assay Cell viability was detected by means of MTT reagent, as described elsewhere (Ruzzene et al., 2002) . Drug interaction was assessed by treating cells with increasing concentrations of both vinblastine and TBB, at a 1:10 concentration ratio (Vbl:TBB), using the combination index (CI) (Giovannetti et al., 2004) , where CIo1, CI ¼ 1, and CI>1 indicate synergistic, additive and antagonistic effects, respectively.
Apoptosis was evaluated by means of the cell detection Elisa kit (Roche), based on the quantification of nucleosomes present in the cytosol of the apoptotic cells, by measuring the absorbance at l 405 -l 490 , following the manufacturer's instructions. About 10 000 cells were used for each determination.
RNA interference experiments R-CEM and S-CEM cells were transfected with a nucleofection device (Amaxa, Inc., Cologne, Germany), using kit C and program X-001, according to the manufacturer instructions. A total of 2.5 Â 10 6 cells were transfected with 1 mM CK2a-specific siRNA pool (siGENOME SMART pool, Dharmacon, Lafayette, CO, USA) or aspecific siRNA (siCONTROL riscfree#1, Dharmacon).
S-U2OS and R-U2OS cells were transfected with 120 nM CK2a-specific siRNA pool or aspecific siRNA, as specified above, using Oligofectamine and following the manufacturer protocols (Invitrogen, S Giuliano, Milanese, Italy). 76 h after nucleofection, cells were collected and partly analysed for apoptosis, partly lysed for western blot to assess the level of CK2a expression and PARP degradation.
U2OS cell transfection U2OS cells, plated onto 60-mm-diameter dishes at about 70% confluency, were transiently transfected with 2 mg of cDNA (pcDNA3.1/myc-His(À) vector expressing CK2a or pcDNA3.1/myc-His(À) empty vector) using 3 ml of FuGENE6 reagent (Roche). At 24 h after transfection, cells were partly lysed for detection of CK2a overexpression, partly used for the analysis of viability upon drug treatment.
Cell lysis and western blot analysis
For total lysate preparation, cells were lysed as described by Di Maira et al. (2005) . For soluble fraction and nuclear extract preparation, cells were lysed by the addition of hypertonic buffer, followed by extraction of nuclear proteins with a hypertonic buffer, as described by Ruzzene et al. (2002) . For subcellular fractionation, cell lysis was performed by sonication in an isotonic buffer (20 mM Tris-HCl, pH 7.5, 0.25 M saccarose, 2 mM EDTA, 2 mM EGTA, 2 mM dithiothreitol, protease inhibitor cocktail complete (Roche), 10 mM NaF, 1 mM okadaic acid, 1 mM Na vanadate, followed by sequential centrifugation at 800 Â g, 10 min (for nuclei precipitation), 8000 Â g, 10 min (mitochondria-enriched fraction) and 140 000 Â g, 60 min (microsomes-enriched fraction and cytosol).
Protein concentration was determined by the Bradford method. Equal amounts of protein were loaded on 11% SDS-PAGE, blotted on Immobilon-P membranes (Millipore, Milano, Italy) , and processed in western blot with the indicated antibody, detected by ECL (enhanced chemiluminescence, Amersham Biosciences, Milano, Italy). Quantitation of the signal was obtained by chemiluminescence detection on a Kodak Image Station 440CF and analysis with the Kodak 1D Image software (Rochester, NY, USA).
RT-PCR analysis
One microgram of total RNA, extracted from plated cells using SV Total RNA isolation system kit (Promega, Milano, Italy), were reverse transcribed in a MJ PT200 thermal cycler with Superscript II (Invitrogen), following manufacturer instructions. Progressive dilutions of the resulting cDNA were subjected to PCR amplification to detect b-actin (with specific primers from Promega) and CK2 a. (N terminus: 5 0 -GA CTACCAGCTGGTTCGAAA-3 0 sense; 5 0 -CCCAGTCTATT AGTCGTA GC-3 0 antisense; C terminus: CGAGTTGC TTCCCGATACTT-5 0 sense; CGTGACTGGTGGTCATAT CG-3 0 antisense).
Immunoprecipitation experiments
About 50-100 mg of cell proteins were used for CK2 or Akt immunoprecipitation, performed with 1-2 ml of anti-CK2a C-terminal antiserum (or pre-immune serum, as a control), or anti-Akt antibody, respectively, followed by addition of protein A-sepharose, as described by Sarno et al. (2001) .
[ 32 P]orthophosphate cell labeling Cells were incubated for the indicated times with culturing medium in the presence of 0.7 mCi/ml. [ 32 P]orthophosphate (GE Healthcare Life Science, Buckinghamshire, UK, PBS11). When present, CK2 inhibitors were added simultaneously to radioactive phosphate. The radioactivity incorporated into cell proteins was detected by SDS-PAGE and blotting, followed by analysis of the membrane with the instrument Cyclone (Packard).
CK2 activity assay
About 0.1-5 mg. of lysate proteins were incubated for 10 min at 301C with 0.1 mM CK2-specific peptide RRRADDSDDDDD, in the presence of phosphorylation reaction mixture (Ruzzene et al., 2002) .
Doxorubicin accumulation measurement
Cells were seeded in 96-well plates and treated at 371C with 25 mM doxorubicin for 30 min, after 30 min preincubation in the absence or in the presence of CK2 inhibitors. After washing with phosphate-buffered saline, cells were lysed in the same buffer, supplemented with 1% (w/v) SDS. Doxorubicin content was determined fluorimetrically (l exc ¼ 485 nm, l em ¼ 590 nm), by comparison to standard curves obtained with known amount of the drug in the same lysis buffer.
